A Phase I, Randomized, Double-blind, Placebo-controlled Study Evaluating The Safety, Hemodynamic And Neurohumoral Effects of a Novel Chimeric Peptide, CD-NP, in Patients With Left Ventricular Assist
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2016
At a glance
- Drugs Cenderitide (Primary)
- Indications Heart failure
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 16 Nov 2016 Results assessing safety of subcutaneous Cenderitide Co-Therapy With LVAD Support presented at the 89th Annual Scientific Sessions of the American Heart Association (2016).
- 29 Aug 2016 Status changed from recruiting to completed.